ASX
Paradigm Biopharmaceuticals Limited
PAR:ASX•Healthcare
Sensitive ASX Announcement
PAR REPORTS SUCCESSFUL ROSS RIVER PHASE 2 CLINICAL TRIAL
Published: 04/06/19, 08:31am (AEST)•5 pages